Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.
about
Combination Radioimmunotherapy Approaches and Quantification of Immuno-PETTumor immunotargeting using innovative radionuclidesSafety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab.Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial.Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial.Application of (212)Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation.Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor XenograftsTargeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.Antibody-mediated delivery of therapeutics for cancer therapy.B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases.Therapeutic Effect of α-Emitting 224Ra-Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer.Targeted and Nontargeted α-Particle Therapies.212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models.Correlation of the absorbed dose to the blood and DNA damage in leukocytes after internal ex-vivo irradiation of blood samples with Ra-224
P2860
Q26747546-64D0EBB8-532B-482D-A1D9-EFFCA70E740DQ28083230-C9384B12-FCDC-412F-A506-481C1749AE3FQ30490448-B287B002-D7FB-41DC-894F-CE9EF3F27A67Q33629621-92740BA8-0AC4-47D5-AB0B-A77C120008C2Q33761180-A990CECF-E0B7-4650-8950-98D43510991DQ36088727-75D1938B-EC5E-46DD-AECB-B364893DFF09Q36105801-7ABB8D78-20C5-47C4-B853-E55A9B3FA9E1Q36105805-460BA9EF-379D-40E7-968A-213E220A6824Q36551498-FDDB872F-58C0-4423-8C1F-D3B7C98A47BDQ36939290-0259C50F-AE74-4AFA-BFC8-EE5324713B66Q37085052-303A52E0-E922-4185-8C23-31D2DC66F009Q38663041-0BD4D36D-974C-4BB4-BCE2-5C5A721CAD84Q38665425-1F626D98-6E7B-4012-9C25-3C4258E996B0Q38768316-809C2001-D2DD-4DC4-9F3F-1CAAA6436EC0Q47152190-F3FBE05A-983C-41BE-B598-111BE3E81350Q49372551-2C899090-5DF7-4C98-A0DF-29652AF930C8Q49967540-F8DA2648-97BF-4C51-A552-7BFF2E46ED8AQ50138482-AD4AA431-BFB2-44A5-88B1-2D1F3C328E66Q58799320-D6CEF44B-3C95-45A0-B485-C6D5F5FB222A
P2860
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Dose escalation and dosimetry ...... y with 212Pb-TCMC-trastuzumab.
@ast
Dose escalation and dosimetry ...... y with 212Pb-TCMC-trastuzumab.
@en
type
label
Dose escalation and dosimetry ...... y with 212Pb-TCMC-trastuzumab.
@ast
Dose escalation and dosimetry ...... y with 212Pb-TCMC-trastuzumab.
@en
prefLabel
Dose escalation and dosimetry ...... y with 212Pb-TCMC-trastuzumab.
@ast
Dose escalation and dosimetry ...... y with 212Pb-TCMC-trastuzumab.
@en
P2093
P2860
P1476
Dose escalation and dosimetry ...... py with 212Pb-TCMC-trastuzumab
@en
P2093
Darrell R Fisher
Desiree Morgan
Eileen Banaga
J Michael Straughn
Julien Torgue
Patty Bunch
Ruby Meredith
P2860
P304
P356
10.2967/JNUMED.114.143842
P407
P50
P577
2014-08-25T00:00:00Z